CompanyGraph
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
002940 · SZSE · China
alkpharm.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.32: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.58%Below 5Y avg (1.18%)
Annual Rate
CNY 0.15Paid annual
Payout Ratio
35.7%Sustainable
Last Ex-Dividend
Jun 22, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.43BCNY805.35M · vs all stocks (USD)
Trailing P/E
43.00xRevenue (TTM)
1.42BCNY210.50M · vs all stocks (USD)
Profit Margin
8.96%Beta
0.7130xvs all stocks
52-Week Change
-47.44%vs all stocks
Market Capitalization
5.43BCNY805.35M · vs all stocks (USD)
Enterprise Value
5.24BCNY776.96M · vs all stocks (USD)
Trailing P/E
43.00xPrice to Sales (TTM)
3.85xPrice to Book (MRQ)
3.23xEnterprise to Revenue
3.69xEnterprise to EBITDA
22.99xGross Margin
36.62%Profit Margin
8.96%Operating Margin
8.94%Return on Assets (TTM)
3.19%Return on Equity (TTM)
8.35%Revenue (TTM)
1.42BCNY210.50M · vs all stocks (USD)
Revenue per Share (TTM)
7.04CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-1.60%Gross Profit (TTM)
547.04MCNY81.13M · vs all stocks (USD)
EBITDA (TTM)
201.91MCNY29.94M · vs all stocks (USD)
Net Income (TTM)
127.19MCNY18.86M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
11.00%Operating Cash Flow (TTM)
199.61MCNY29.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
86.96MCNY12.90M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1500CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.58%vs all stocks
5-Year Average Dividend Yield
1.18%vs all stocks
Payout Ratio
35.71%Minority Interest (Equity)
239.94MCNYFY2025 · Dec 31, 2025Revenue
1.42BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
862.36MCNYFY2025 · Dec 31, 2025Gross Profit
562.45MCNYFY2025 · Dec 31, 2025Operating Income
203.09MCNY30.12M · vs all stocks (USD)
Pre-tax Income
180.28MCNYFY2025 · Dec 31, 2025Income Tax Expense
23.54MCNYFY2025 · Dec 31, 2025Net Income
156.73MCNYFY2025 · Dec 31, 2025EBIT
193.28MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
273.36MCNYFY2025 · Dec 31, 2025Research & Development
144.05MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
168.13MCNYFY2025 · Dec 31, 2025Other Operating Expenses
16.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
13.67MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
13.00MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.6200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.6200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
202.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
202.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
156.73MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-31.29MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
193.88MCNYFY2025 · Dec 31, 2025Free Cash Flow
144.15MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
336.84MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
156.73MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.64MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-27.17MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
59.68MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.73MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.50BCNYFY2025 · Dec 31, 2025Sale of Investments
1.45BCNYFY2025 · Dec 31, 2025Other Investing Activity
22.06MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-85.98MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
191.71MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-227.92MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-57.60MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.91MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-95.71MCNYFY2025 · Dec 31, 2025Shares Outstanding
201.73MSharesUpdated Aug 19, 2026Float Shares
98.52MSharesUpdated Aug 19, 2026% Held by Insiders
48.63%vs all stocks
% Held by Institutions
1.92%vs all stocks
Total Cash (MRQ)
891.09MCNY132.15M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.54CNYUpdated Aug 19, 2026Total Debt (MRQ)
571.62MCNY84.77M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3021xCurrent Ratio (MRQ)
1.84xBook Value per Share (MRQ)
8.39CNYUpdated Aug 19, 2026Total Assets
2.95BCNY437.61M · vs all stocks (USD)
Total Current Assets
1.49BCNYFY2025 · Dec 31, 2025Total Liabilities
1.08BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.46BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
270.56MCNYFY2025 · Dec 31, 2025Total Current Liabilities
813.03MCNYFY2025 · Dec 31, 2025Cash
685.24MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.17MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
687.41MCNYFY2025 · Dec 31, 2025Other Short-term Investments
102.26MCNYFY2025 · Dec 31, 2025Accounts Receivable
176.03MCNYFY2025 · Dec 31, 2025Inventory
447.47MCNYFY2025 · Dec 31, 2025Accounts Payable
434.09MCNYFY2025 · Dec 31, 2025Short-term Debt
206.80MCNYFY2025 · Dec 31, 2025Other Current Liabilities
22.96MCNYFY2025 · Dec 31, 2025Long-term Debt
242.26MCNYFY2025 · Dec 31, 2025Common Stock (Book)
201.73MCNYFY2025 · Dec 31, 2025Retained Earnings
709.12MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.87BCNY276.91M · vs all stocks (USD)
Treasury Stock
84.10MCNYFY2025 · Dec 31, 202552-Week Low
23.11CNYUpdated Aug 19, 202652-Week High
58.93CNYUpdated Aug 19, 202652-Week Change
-47.44%vs all stocks
Beta
0.7130xvs all stocks
50-Day MA
27.07CNYUpdated Aug 19, 2026200-Day MA
32.90CNYUpdated Aug 19, 2026Avg 10-Day Volume
11.81MSharesUpdated Aug 19, 2026Avg 30-Day Volume
13.55MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.6300CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.32: safe zoneNotable
Altman Z-Score: 4.32
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengda Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
Esperion Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangsu Xinquan Automotive Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Super Telecom Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Shengjian Technology Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated